Combatting COVID-19: 21 Innovative Efforts

May 15, 2020 | Blog | 0 comments

Daniel Gigante

Note: This post was co-written by Sabyasachi Dash, PhD

At the time of writing, more than 2.7 million cases of COVID-19 have been reported globally. Development of a vaccine against the novel coronavirus, SARS-CoV-2, require an investment of 12-18 months. Worse yet, the drug discovery pipeline including the critical steps of discovery of a therapeutic, pre-clinical testing, clinical testing, approval and commercialization can range in years (5-6+).

The process of identifying relevant therapeutics varies across laboratories. For instance, identification of therapeutic antibodies such as monoclonal (mAb) antibodies with desirable characteristics requires an amalgamation of high-end techniques and precision-based high-throughput platforms for testing and validation.

We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.

1. Abbvie – Abbvie is working on a small molecule combination therapy originally used as an anti-retroviral against HIV. The combination involves Lopinavir/Ritonavir and is currently in stage III. It works by inhibiting the function of viral protease enzymes. Read more here.

2. Regeneron – Regeneron is developing mAb Therapy leveraging its proprietary VelociSuite and VelocImmune technologies. It’s currently in preclinical stages. Learn more here.

3. Ascletis – Ascletis is working on Danoprevir + Ritonavir, a stage I small molecule drug representing another class of viral protease inhibitors classically used against Hepatitis C virus. Read more here.

4. Sanofi – Sanofi is working on Plaquenil (Hydroxychloroquine), an immunosuppressive small molecule currently in preclinical stages. The drug works by increasing lysosomal pH in immune cells, inhibiting Toll like receptor, reducing inflammation, and inducing interferon production. Read more here. In addition, Sanofi is working on a DNA-based nucleic acid therapeutic that leverages recombinant DNA technology. Read more here.

5. Takeda – Takeda is working on Poly-Ab therapy (TAK-888). Currently in preclinical stages, it works using pathogen specific antibodies from recovered or vaccinated individuals. Read more here.

6. Hoth Therapeutics & Voltron Therapeutics – Hoth Therapeutics is teaming with Voltron on a self-assembling vaccine. Currently in preclinical stages, it uses a combination of chemical adjuvants which activate immune response while targeting viral factors (proteins and nucleic acids). Read more here.

7. Moderna – Moderna is working on mRNA-1273. Currently in stage I, the drug is an RNA-based nucleic acid therapeutic. Read more here.

8. CanSino Biologics – CanSinoBio is working on Ad5-nCoV. Currently in stage II, it’s a recombinant vaccine therapeutic using adenovirus based viral vector technology. Read more about it here.

9. Arcturus Therapeutics – Arcturus is working on a COVID-19 vaccine currently in preclinical stages. The vaccine is an mRNA-based nucleic acid therapeutic. Read more here.

10. AbCellera & Eli Lilly – AbCellera and Lilly have teamed up to work on an antibody therapy currently in preclinical stages. You can read more about the collaboration and their work here.

11. GSK & Clover Biopharmaceuticals – GSK and Clover are working on a protein based vaccine. It uses timer-tag technology and is currently in preclinical stages. Read more here.

12. Inovio Pharmaceuticals – Inovio is working on INO-4800, a COVID-19 vaccine currently in preclinical stages. It’s a DNA-based nucleic acid therapeutic. Read more here.

13. Nuritas – Nuritas is focusing on discovery of stable peptides to target virus-host interaction. They’re leveraging their proprietary Nuritas Peptide Finder platform. Read more here.

14. Sanofi & Regeneron – Sanofi and Regeneron make our list again, here teaming up on a mAb therapeutic, Kevzara. Currently in stage II/III, the technology works by leveraging mAb inhibiting cytokine (IL6) in host cells. Read more here.

15. Pfizer & BioNTech – Pfizer and BioNTech have teamed up to work on an mRNA vaccine (BNT162). Currently in preclinical stages, the drug is an RNA-based nucleic acid therapeutic. Read more here.

16. SOM Biotech and Ewha Womans University – SOM Biotech and Ewha are leveraging artificial intelligence based screening technology. The three candidates they’re currently working on inhibit the main protease of SARS-CoV-2. Read more here.

17. Johnson & Johnson – Johnson & Johnson is working on a COVID-19 vaccine that uses the proprietary Advac PER.66 technology. It is currently in preclinical stages. You can read more about their work here.

18. Vaccitech – Vaccitech is working on Lopinavir + Ritonavir which is currently in stage IIb. The treatment leverages small molecule inhibitors. Learn more here.

19. GSK & Vir Biotechnology – GSK makes our list again, here teaming up with Vir. The team is working on a gene-editing based mAb therapeutic, currently in preclinical stages. Read more here.

20. Gilead – Gilead is working on Remdesivir. Currently in stage III, the drug is an adenosine analogue and effectively targets the viral RNA, causing premature termination by interfering with the activity of RNA-dependent RNA polymerase enzyme. Read more here.

21. ImmunoPrecise and EVQLV – Of course, we couldn’t leave out our own efforts. ImmunoPrecise and EVQLV are working on therapeutic and vaccine candidates using high-throughput computational antibody design. Although we’ve discussed our work at length on this blog, you can check out the official release here.

This list is nowhere near exhaustive. We welcome, in the form of comments below or by contacting us directly, any new information on promising treatments for COVID-19.


Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest